JP2024525578A5 - - Google Patents
Info
- Publication number
- JP2024525578A5 JP2024525578A5 JP2024500303A JP2024500303A JP2024525578A5 JP 2024525578 A5 JP2024525578 A5 JP 2024525578A5 JP 2024500303 A JP2024500303 A JP 2024500303A JP 2024500303 A JP2024500303 A JP 2024500303A JP 2024525578 A5 JP2024525578 A5 JP 2024525578A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleoside
- composition
- modified rna
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163218685P | 2021-07-06 | 2021-07-06 | |
| US63/218,685 | 2021-07-06 | ||
| PCT/US2022/073463 WO2023283576A1 (en) | 2021-07-06 | 2022-07-06 | P7 containing nucleoside-modified mrna-lipid nanoparticle lineage vaccine for hepatitis c virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525578A JP2024525578A (ja) | 2024-07-12 |
| JP2024525578A5 true JP2024525578A5 (cg-RX-API-DMAC7.html) | 2025-07-14 |
Family
ID=84802063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500303A Pending JP2024525578A (ja) | 2021-07-06 | 2022-07-06 | Ｃ型肝炎ウイルスのためのＰ７含有ヌクレオシド－改変されたｍＲＮＡ－脂質ナノ粒子系統ワクチン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240358821A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4366770A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024525578A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117915946A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022307932A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3224943A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023283576A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004005524A1 (en) * | 2002-07-02 | 2004-01-15 | Merck & Co., Inc. | Hepatitis c virus particle formation |
| EP1537206B1 (en) * | 2002-09-13 | 2009-05-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Infectious hepacivirus pseudo-particles containing functional e1, e2 envelope proteins |
| US8178086B2 (en) * | 2006-01-04 | 2012-05-15 | Novartis Vaccines And Diagnostics, Inc. | Activation of HCV specific T cells |
| AU2016253972B2 (en) * | 2015-04-27 | 2020-01-02 | Acuitas Therapeutics Inc. | Nucleoside-modified RNA for inducing an adaptive immune response |
| EP3445396A4 (en) * | 2016-04-22 | 2020-03-11 | Integrated Research Associates, LLC | IMPROVED PROCESS FOR PRODUCING VIRUS-LIKE PARTICLES |
| CN110402145A (zh) * | 2016-10-26 | 2019-11-01 | 莫得纳特斯公司 | 用于增强免疫应答的信使核糖核酸及其使用方法 |
| US11596679B2 (en) * | 2017-04-27 | 2023-03-07 | Vanderbilt University | Hepatitis C virus gene sequences and methods of use therefor |
| WO2019210144A1 (en) * | 2018-04-27 | 2019-10-31 | Vanderbilt University | Broadly neutralizing antibodies against hepatitis c virus |
-
2022
- 2022-07-06 CA CA3224943A patent/CA3224943A1/en active Pending
- 2022-07-06 WO PCT/US2022/073463 patent/WO2023283576A1/en not_active Ceased
- 2022-07-06 US US18/577,550 patent/US20240358821A1/en active Pending
- 2022-07-06 CN CN202280060200.9A patent/CN117915946A/zh active Pending
- 2022-07-06 JP JP2024500303A patent/JP2024525578A/ja active Pending
- 2022-07-06 EP EP22838562.1A patent/EP4366770A4/en active Pending
- 2022-07-06 AU AU2022307932A patent/AU2022307932A1/en active Pending